Rossella Musa

This inventor holds 17 USPTO granted patents and 8 published patent applications, plus 6 CIPO patents and 11 EPO patents. Top assignees: Chiesi Farmaceutici S.p.a., Vectura Gmbh. Active years: 2003-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rossella Musa. Retrieved from https://idiyas.com/inventor/rossella-musa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 70.6

CIPO Patents = 6

EPO Patents = 11 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 229(Granted Patents)

Company Filing History:

11 out of 341

Chiesi Farmaceutici S.p.a.

Years Active: 2003-2020

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10857169 - Tobramycin magnesium stearate microparticles for inhalation, compositions thereof, and methods of making and using the same (2020-12-08),

2. 10561613 - Method of making particles for use in a pharmaceutical composition (2020-02-18),

3. 9808422 - Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation (2017-11-07),

4. 9566239 - Pharmaceutical formulations for dry powder inhalers (2017-02-14),

5. 9445999 - Process for preparing carrier particles for dry powders for inhalation (2016-09-20),

6. 9402825 - Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation (2016-08-02),

7. 9351928 - Method of making particles for use in a pharmaceutical composition (2016-05-31),

8. 8974831 - Process for preparing carrier particles for dry powders for inhalation (2015-03-10),

9. 8871274 - Pharmaceutical formulations for dry powder inhalers (2014-10-28),

10. 8512753 - Micronized particles of low-dosage strength active agents for powder formulations for inhalation (2013-08-20),

11. 8182791 - Formulations for use in inhaler devices (2012-05-22),

12. 7541022 - Pharmaceutical formulations for dry powder inhalers (2009-06-02),

13. 7223748 - Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets (2007-05-29),

14. 7132115 - Modified carrier particles for use in dry powder inhalers (2006-11-07),

15. 6884794 - Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets (2005-04-26),

Title: Rossella Musa: Innovator in Pharmaceutical Formulations

Introduction

Rossella Musa is a prominent inventor based in Parma, Italy, known for her significant contributions to the field of pharmaceutical formulations. With a total of 17 patents to her name, she has made remarkable advancements in the development of inhalable medications.

Latest Patents

Among her latest patents is the invention of tobramycin magnesium stearate microparticles for inhalation. This innovative formulation is designed to treat bacterial infections associated with certain pulmonary diseases. Additionally, she has developed a method for making composite excipient particles for use in pharmaceutical compositions. This method involves a milling step that allows for the production of small-sized particles with relatively low input of time and energy, making them suitable for inhalable pharmaceutical compositions.

Career Highlights

Throughout her career, Rossella has worked with notable companies in the pharmaceutical industry, including Chiesi Farmaceutici S.p.a. and Vectura GmbH. Her work has focused on enhancing the efficacy and delivery of medications, particularly in the area of respiratory treatments.

Collaborations

Rossella has collaborated with esteemed colleagues such as John Nicholas Staniforth and David Alexander Vodden Morton, contributing to the advancement of pharmaceutical sciences through teamwork and shared expertise.

Conclusion

Rossella Musa's innovative work in pharmaceutical formulations has significantly impacted the treatment of pulmonary diseases. Her dedication to research and development continues to pave the way for new therapeutic options in the medical field.

Profile summary based on public USPTO records.